386 related articles for article (PubMed ID: 30537506)
1. The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.
Van den Eynde M; Mlecnik B; Bindea G; Fredriksen T; Church SE; Lafontaine L; Haicheur N; Marliot F; Angelova M; Vasaturo A; Bruni D; Jouret-Mourin A; Baldin P; Huyghe N; Haustermans K; Debucquoy A; Van Cutsem E; Gigot JF; Hubert C; Kartheuser A; Remue C; Léonard D; Valge-Archer V; Pagès F; Machiels JP; Galon J
Cancer Cell; 2018 Dec; 34(6):1012-1026.e3. PubMed ID: 30537506
[TBL] [Abstract][Full Text] [Related]
2. Multiverse of immune microenvironment in metastatic colorectal cancer.
Van den Eynde M; Mlecnik B; Bindea G; Galon J
Oncoimmunology; 2020 Sep; 9(1):1824316. PubMed ID: 33457100
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
Mlecnik B; Van den Eynde M; Bindea G; Church SE; Vasaturo A; Fredriksen T; Lafontaine L; Haicheur N; Marliot F; Debetancourt D; Pairet G; Jouret-Mourin A; Gigot JF; Hubert C; Danse E; Dragean C; Carrasco J; Humblet Y; Valge-Archer V; Berger A; Pagès F; Machiels JP; Galon J
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922789
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
5. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
7. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
9. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.
Maker AV; Ito H; Mo Q; Weisenberg E; Qin LX; Turcotte S; Maithel S; Shia J; Blumgart L; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
Cancer Immunol Res; 2015 Apr; 3(4):380-8. PubMed ID: 25600439
[TBL] [Abstract][Full Text] [Related]
10. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
12. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
13. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages.
Silva-Figueroa A; Villalobos P; Williams MD; Bassett RL; Clarke CN; Lee JE; Busaidy NL; Perrier ND
Surgery; 2018 Nov; 164(5):960-964. PubMed ID: 30033186
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
16. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Mlecnik B; Bindea G; Kirilovsky A; Angell HK; Obenauf AC; Tosolini M; Church SE; Maby P; Vasaturo A; Angelova M; Fredriksen T; Mauger S; Waldner M; Berger A; Speicher MR; Pagès F; Valge-Archer V; Galon J
Sci Transl Med; 2016 Feb; 8(327):327ra26. PubMed ID: 26912905
[TBL] [Abstract][Full Text] [Related]
17. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine.
Herfs M; Roncarati P; Koopmansch B; Peulen O; Bruyere D; Lebeau A; Hendrick E; Hubert P; Poncin A; Penny W; Piazzon N; Monnien F; Guenat D; Mougin C; Prétet JL; Vuitton L; Segers K; Lambert F; Bours V; de Leval L; Valmary-Degano S; Quick CM; Crum CP; Delvenne P
Br J Cancer; 2018 May; 118(10):1302-1312. PubMed ID: 29700411
[TBL] [Abstract][Full Text] [Related]
18. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
19. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
